Stocks and Investing Stocks and Investing
Thu, October 19, 2023

Matt Miksic Maintained (ABT) at Buy with Increased Target to $133 on, Oct 19th, 2023


Published on 2024-10-28 06:58:36 - WOPRAI, Matt Miksic
  Print publication without navigation


Matt Miksic of Barclays, Maintained "Abbott Laboratories" (ABT) at Buy with Increased Target from $132 to $133 on, Oct 19th, 2023.

Matt has made no other calls on ABT in the last 4 months.



There are 3 other peers that have a rating on ABT. Out of the 3 peers that are also analyzing ABT, 2 agree with Matt's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Mike Polark of "Wolfe Research" Upgraded from Sell to Hold on, Friday, July 21st, 2023
  • Anthony Petrone of "Mizuho" Initiated at Hold with Increased Target to $115 on, Friday, July 21st, 2023


This is the rating of the analyst that currently disagrees with Matt


  • Joanne Wuensch of "Citigroup" Maintained at Strong Buy with Decreased Target to $122 on, Monday, October 2nd, 2023

Contributing Sources